Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 17, 2007 - Issue 4
Submit an article Journal homepage
174
Views
24
CrossRef citations to date
0
Altmetric
Review

Pleuromutilin antibacterial agents: patent review 2001 – 2006

Oludotun A Phillips Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait. [email protected]
&
Leyla H Sharaf Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait
Pages 429-435 | Published online: 19 Apr 2007

Bibliography

  • BOYD B, CASTANER J: Retapamulin. Drugs Fut. (2006) 31(2):107-113.
  • KAVANAGH F, HERVEY A, ROBBINS WJ: Antibiotic substances from Basidomyces. VIII. Pleurotus mutilis and Pleurotus passeckerianus. Proc. Natl. Acad. Sci. USA (1951) 37:570-574.
  • HUNT E: Pleuromutilin antibiotics. Drugs Fut. (2000) 25:1163-1168.
  • SCHLÜNZEN F, PYETAN E, FUCINI P, YONATH A, HARMS JM: Inhibition of peptide bond formation by pleuromutilins: the structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin. Mol. Microbiol. (2004) 54(5):1287-1294.
  • POULSEN SM, KARLSSON M, JOHANSSON LB, VESTER B: The pleuromutilin drugs tiamulin and valnemulin bind to the RNA at the peptidyl transferase centre on the ribosome. Mol. Microbiol. (2001) 41(5):1091-1099.
  • LONG KS, HANSEN LH, JAKOBSEN L, VESTER B: Interaction of pleuromutilin derivatives with the ribosomal peptidyl transferase center. Antimicrob. Agents Chemother. (2006) 50(4):1458-1462.
  • BROOKS G, BURGESS W, COLTHURST D et al.: Pleuromutilins. Part 1. The identification of novel mutilin 14-carbamates. Bioorg. Med. Chem. (2001) 9:1221-1231.
  • LONG KS, POEHLSGAARD J, KEHRENBERG C, SCHWARZ S, VESTER B: The Cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins and streptogramin A antibiotics. Antimicrob. Agents Chemother. (2006) 50(7):2500-2505.
  • SPRINGER DM, SORENSON ME, HUANG S et al.: Synthesis and activity of a C-8 keto pleuromutilin derivative. Bioorg. Med. Chem. Lett. (2003) 13:1751-1753.
  • STRESSER DM, BROUDY MI, HO T et al.: Highly selective inhibition of human CYP3A in vitro by azamulin and evidence that inhibition is irreversible. Drug Metab. Disp. (2004) 32(1):105-112.
  • HEILMANN C, JENSEN L, JENSEN JS et al.: Treatment of resistant Mycoplasma infection in immunocompromised patients with a new pleuromutilin antibiotic. J. Inf. (2001) 43:234-238.
  • RITTENHOUSE S, BISWAS S, BROSKEY J et al.: Selection of retapamulin, a novel pleuromutilin for topical use. Antimicrob. Agents Chemother. (2006) 50(11):3882-3885.
  • FREE A, ROTH E, DALESSANDRO M et al.: Retapamulin ointment twice daily for 5 days versus oral cephalexin twice daily for 10 days for empiric treatment of secondarily infected traumatic lesions of the skin. SKINmed: Dermatology for the clinician (2006) 5(5):224-232.
  • GOLDSTEIN EJ, CITRON DM, MERRIAM CV, WARREN YA, TYRRELL KL, FERNANDEZ HT: Comparative in vitro activities of retapamulin against 141 clinical isolates of Propionibacterium spp., including 117 P. acnes isolates. Antimicrob. Agents Chemother. (2006) 50(1):379-381.
  • ANNOTATED PATENT SELECTIONS: Expert Opin. Ther. Patents (2004) 14(5):749-772.
  • BOGGS AF, HECKER SJ: A tour of recent patent applications addressing antibacterial resistance. Expert Opin. Ther. Patents (2002) 12(8):1159-1172.
  • PHILLIPS OA, MATOWE WC: Antibacterial agents: patent highlights January to June 2002. Curr. Opin. Investig. Drugs (2002) 3(12):1701-1711.
  • CENTERS FOR DISEASE CONTROL AND PREVENTION: Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs Worldwide, 2000 – 2004. Morbid. Mortal. Wkly. Rep. (2006) 55(11):301-305.
  • ZULLO A, HASSAN C, ERAMO A, MORINI S: Helicobacter pylori therapy: what is coming? Expert Opin. Ther. Patents (2006) 16(8):1107-1112.
  • LUNDSTROM TS, SOBEL JD: Antibiotics for Gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid and daptomycin. Infect. Dis. Clin. N. Am. (2004) 18:651-668.
  • WANG J, SOISSON SM, YOUNG K: Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature (2006) 441:358-361.

Patents

Websites

  • http://www.docguide.com/news/content. nsf/news/ Doctors’ guide website (2006).
  • http://www.gsk.com/ControllerServlet?appId=4&pageId-402&newsid=953 GlaxoSmithKline website press release (2006).
  • http://www.gsk.com/investors/pp_pipeline_ standard.htm GlaxoSmithKline website (2006).
  • http://www.nabriva.com/html/program.html NABRIVA website (2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.